What are the new drugs for Amyotrophic Lateral Sclerosis?

Introduction to Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder primarily affecting motor neurons in both the motor cortex and the spinal cord. It is characterized by progressive muscle weakness, atrophy, spasticity, fasciculations, and eventual paralysis, leading most often to respiratory failure within three to five years after diagnosis. Patients might additionally suffer from dysarthria (difficulty speaking), dysphagia (difficulty swallowing), and in some cases cognitive or behavioral changes such as frontotemporal dementia. The heterogeneity in clinical presentation – with some individuals showing rapid progression and others a more indolent course – poses challenges for diagnosis and therapeutic interventions. 

Current Treatment Landscape 
Historically, the treatment landscape for ALS has been marked by a very limited number of therapeutic options. Riluzole and edaravone have been the only drugs approved by regulatory agencies such as the US FDA for decades, each producing only modest benefits in terms of survival prolongation and slowing disease progression. Riluzole is believed to work primarily by reducing glutamate-mediated excitotoxicity, whereas edaravone functions as an antioxidant scavenging free radicals. Despite these treatments, the unmet medical need remains high, given the aggressive nature of ALS and the minimal impact on the overall survival or quality of life. This therapeutic deficiency has triggered an intense research effort to identify and develop new drugs with stronger efficacy and improved safety profiles.

Recent Developments in ALS Drug Treatments

The landscape is now evolving with the advent of several novel therapeutic candidates – both those that have recently been approved and others currently undergoing clinical trials. These new drugs target various aspects of the underlying pathology of ALS and represent a multi-pronged approach to treating this multifactorial disease.

Newly Approved Drugs 
One of the landmark advancements in recent years is the approval of AMX0035. AMX0035 is a combination therapy composed of sodium phenylbutyrate and taurursodiol. Its mechanism is to alleviate endoplasmic reticulum stress and mitochondrial dysfunction, both of which contribute to motor neuron death. Clinical trials have demonstrated that AMX0035 can slow the deterioration of functional status and even extend survival modestly, providing a new ray of hope for patients who had very few options beyond riluzole and edaravone. 

Another new drug that has emerged is Tofersen, an antisense oligonucleotide (ASO) specifically targeting SOD1 gene mutations, which are responsible for a subset of familial ALS cases. By binding to SOD1 messenger RNA, tofersen reduces the synthesis of the toxic SOD1 protein. Although its clinical efficacy in terms of endpoint improvements has been debated, it remains a promising therapeutic candidate that highlights the significance of genetic stratification in ALS treatments. 

In addition to these molecularly targeted therapies, some innovative drugs have also been introduced via alternative approaches. Recently, a cell‐based therapy known as NurOwn has been developed. NurOwn is derived from autologous mesenchymal stem cells that are induced to secrete neurotrophic factors. This approach is based on the concept of using the patient’s own cells to modulate the local neurotrophic environment and promote neuroprotection. It has been evaluated in clinical trials and represents a paradigm shift away from small molecule drugs to biologically based interventions. 

Drugs in Clinical Trials 
Beyond the few that have already received regulatory approvals, a variety of compounds are currently in various phases of clinical trials. These new candidates target distinct pathological mechanisms and are developed using advanced insights into ALS biology:

• Masitinib is a tyrosine kinase inhibitor that has been studied as an add-on therapy to riluzole. In a phase II/III clinical trial, compared to placebo, the combination of riluzole plus masitinib (at a dose of 4.5 mg/kg per day) slowed the rate of functional decline by approximately 27%. Its anti-inflammatory and neuroprotective properties, particularly in terms of modulating microglial activity, make it a promising agent for further study.

• Reldesemtiv is a fast skeletal muscle troponin activator that aims to improve muscle function by enhancing calcium sensitivity in muscle fibers. Although not a direct neuroprotective agent, reldesemtiv addresses the symptomatic aspect of ALS by potentially improving the strength and endurance of weakened muscles. In clinical trials such as FORTITUDE-ALS, exploratory endpoints have indicated that patients on reldesemtiv show less decline over 12 weeks compared to placebo, an effect that persisted even in the follow-up period.

• NU-9 is a novel compound identified in recent preclinical research. Developed by researchers at Northwestern University, NU-9 represents a drug candidate with a unique mechanism – one that lengthens the axons of affected upper motor neurons to assist in signal propagation. Early animal studies have shown promising results in terms of axon growth and neuroprotection, and NU-9 is projected to enter early-stage human trials within the coming years.

• Other experimental drugs in the clinical pipeline include those targeting oxidative stress, neuroinflammation, and protein aggregation. Some candidates are also exploring combination therapies where multiple agents with complementary mechanisms are administered together. This approach of “drug combinations” seeks to tackle the multifactorial aspects of ALS simultaneously and may involve pairing agents such as glutamate antagonists, antioxidants, and anti-inflammatory drugs in a single regimen. Numerous phase II and phase III trials are currently investigating these strategies, reflecting a shift towards multi-target therapy in ALS drug development.

These drugs reflect a broad spectrum of novel approaches—from small molecules and biologics engineered to modulate specific pathogenic pathways to cell-based therapies aimed at altering the disease environment. The diversity of these candidates underscores the evolution of ALS treatment from a “one-size-fits-all” model to a more personalized medicine approach.

Mechanisms of Action

Understanding the mechanisms of action of these new drugs provides insight into how they might modify disease progression or alleviate symptoms more effectively than previous therapies. The new drugs for ALS target a variety of underlying pathological processes.

How New Drugs Target ALS 
Each novel drug or therapeutic candidate proposes a different way of tackling ALS pathology: 

• AMX0035’s mechanism centers on cellular stress pathways. It is designed to mitigate endoplasmic reticulum (ER) stress and improve mitochondrial function, thereby preventing cell apoptosis. By alleviating cellular stress, AMX0035 not only improves motor neuron survival but also contributes to improved bioenergetic efficiency in neurons.

• Tofersen, on the other hand, utilizes a genetic approach. As an antisense oligonucleotide (ASO), it specifically targets the SOD1 messenger RNA for degradation, reducing the production of the mutant SOD1 protein. This reduction in toxic protein accumulation may slow neurodegeneration in patients harboring SOD1 mutations.

• Masitinib functions as a tyrosine kinase inhibitor. It exerts its effects primarily by modulating the inflammatory response in the central nervous system. By inhibiting certain kinases involved in microglial activation, masitinib helps reduce neuroinflammation, which is believed to be a key contributor to motor neuron damage in ALS.

• Reldesemtiv’s mechanism is somewhat different because it addresses the downstream consequences of motor neuron degeneration. Rather than directly protecting motor neurons, reldesemtiv works on the muscle tissue by increasing the sensitivity of the contractile apparatus to calcium. This improvement in muscle contractility helps maintain physical function and may provide symptomatic relief even if the underlying neurodegenerative process continues.

• NurOwn represents a biologically based approach. By using autologous mesenchymal stem cells that are induced to secrete neurotrophic factors, NurOwn aims to create a supportive microenvironment for motor neurons. This trophic support can aid in reducing neurodegeneration and promoting neural repair through local paracrine effects.

• NU-9, though still in preclinical development, is designed to promote axon elongation. Its proposed mechanism involves enhancing the intrinsic capacity of neurons to extend their processes, thus potentially compensating for the loss of connectivity that occurs as a result of ALS-induced degeneration.

Comparative Effectiveness 
Comparatively, the effectiveness of these new drugs is assessed not only based on their molecular targets but also through their impact on clinical endpoints such as functional decline, survival, and quality of life:

• AMX0035 has been shown in clinical studies to result in a statistically significant slowing of the ALS Functional Rating Scale score decline and offers a modest survival benefit. Its advantage lies in its dual targeting of cellular stress and mitochondrial dysfunction—a common pathological thread in ALS. 

• Tofersen’s effectiveness is limited to a genetically defined subset of ALS patients (those with SOD1 mutations). While it may not be broadly applicable to all ALS patients, its efficacy in reducing SOD1 levels suggests it could be highly effective for the targeted population.

• Masitinib, when used in conjunction with riluzole, has demonstrated promising results in slowing disease progression. Its anti-inflammatory actions offer a unique angle by targeting neuroinflammation—a process that may be underappreciated in traditional ALS therapies—and its effectiveness has been supported by phase II/III trial data.

• Reldesemtiv is primarily focused on functional improvement rather than direct neuroprotection. The preservation of muscle strength and functional capacity is clinically significant, particularly as patients’ quality of life hinges on the ability to perform daily activities.

• Cell-based therapies such as NurOwn may not yield dramatic changes in conventional clinical endpoints initially, but they offer the potential for remodeling the disease environment and promoting long‐term motor neuron survival. Their ultimate comparative effectiveness is still under evaluation in long-term studies.

• NU-9, while promising in preclinical models, requires further testing to determine whether its axon-lengthening effects will translate into meaningful clinical benefits in terms of slowed disease progression or improved motor function.

Comparative studies and network meta-analyses in ALS clinical trials are beginning to explore these differences. Although direct comparisons in head-to-head trials are limited due to the heterogeneity of ALS and the varied patient populations, early indications suggest that combination therapies or ones with multimodal mechanisms (e.g., AMX0035) might offer a slightly improved clinical benefit over monotherapies focused on a single mechanism.

Challenges and Future Directions

Current Challenges in ALS Treatment 
Despite the promising advances, new drug development for ALS still faces numerous challenges that have hampered the translation of preclinical successes into widespread clinical benefit:

• Heterogeneity of ALS: ALS is a multifactorial, heterogeneous disease. This means that patients exhibit different underlying molecular and cellular pathologies. Drugs like tofersen target a specific genetic subset (SOD1 mutations) while others, like AMX0035, attempt to address common pathological pathways like ER stress. However, this heterogeneity may lead to variable responses in clinical trials and creates difficulties in designing studies with sufficiently powered cohorts. 

• Multidimensional Outcome Measurements: Clinical trials in ALS typically use composite scales such as the ALS Functional Rating Scale-Revised (ALSFRS-R). However, the multidimensionality of these endpoints can dilute the observed treatment effect if different subscales (e.g., bulbar, motor, respiratory) do not respond uniformly to therapy. This makes it challenging to discern the true efficacy of a drug if its effects are limited to one domain while others remain unchanged. 

• Delivery Challenges: For drugs like ASOs (e.g., tofersen) and cell-based therapies (e.g., NurOwn), delivering the therapeutic effectively to the central nervous system remains critical. The blood-brain barrier and blood-spinal cord barrier severely constrain drug delivery, affecting dose, frequency, and consequently side-effect profile. Advanced delivery systems, including nanotechnology-based carriers, are being explored but are not yet widely adopted.

• Limited Biomarkers: Reliable biomarkers for ALS progression and drug target engagement are still lacking. Without robust biomarkers, it is difficult to stratify patients, monitor treatment response rapidly, or adapt trial designs effectively during the study. Integrated biomarker research is essential for future drug development to reduce uncertainty and tailor therapies more precisely.

• Regulatory and Economic Barriers: The rarity of ALS and the high costs associated with conducting large-scale phase III trials pose significant economic challenges. Moreover, differing regulatory requirements across regions complicate the approval process for new therapies, calling for harmonized endpoints and adaptive trial designs.

Future Prospects and Research Directions 
The promising recent developments pave the way for several future directions in ALS drug development:

• Personalized Medicine and Genetic Stratification: Future clinical trials in ALS are likely to benefit from improved patient phenotyping and genetic stratification. Drugs such as tofersen, which are specific for SOD1 mutations, are precursors to a more personalized approach wherein therapies are tailored according to the patient's genetic and molecular profile. This approach can enable more targeted therapies and potentially higher treatment efficacy for defined subgroups.

• Combination Therapy: Given the multifactorial aspects of ALS, combination therapies that target different pathological processes simultaneously may yield better clinical outcomes than single-agent therapies. For instance, combining agents that reduce excitotoxicity with those that mitigate neuroinflammation or support mitochondrial function could provide synergistic effects. Future trial designs will need to explore multidrug regimens and adaptive designs to assess combinatorial efficacy.

• Innovative Trial Designs and Digital Health: Emerging trial designs, such as adaptive trials and remote monitoring methodologies (“ALS AT HOME”), promise to reduce patient burden, lower sample size requirements, and accelerate data collection. Digital health tools – including wearable devices and mobile apps – can provide real-time data and improve endpoint accuracy, thereby enhancing the statistical power of trials and allowing for quicker adjustments in study design.

• Nanotechnology and Advanced Delivery Systems: Overcoming delivery barriers is essential for drugs such as ASOs and cell-based therapies. Nanotechnology-based strategies are being explored to improve the bioavailability, stability, and targeted delivery of these therapies to the central nervous system. Success in these areas would not only enhance drug efficacy but also reduce systemic side effects.

• Development of Reliable Biomarkers: Concerted research efforts are underway to identify and validate biomarkers that can effectively measure disease progression, predict responsiveness to therapy, and verify target engagement. Advanced proteomic and genomic technologies could unveil candidate biomarkers, which in turn might facilitate earlier diagnosis and more responsive and adaptive trial methodologies.

• Cell-based and Gene Therapies: The future may see an expanded role for biologics, including therapies such as NurOwn and gene editing approaches (for example, CRISPR/Cas9 strategies to address genetic mutations). These therapies could potentially reverse or halt motor neuron degeneration if optimized for safety and efficacy. Continued research in this area is promising, but rigorous long-term studies remain necessary.

• Enhanced Regulatory Guidance and Collaborative Consortia: Future success in ALS drug development will also depend on closer collaboration among regulatory agencies, pharmaceutical companies, patient advocacy groups, and clinical researchers. Harmonized guidelines for trial endpoints and adaptive trial approaches, backed by real-world data and patient registries, can streamline the development process and foster innovative solutions in this challenging field.

Conclusion 
In summary, the new drugs for ALS reflect a transformative phase in the fight against this devastating neurodegenerative disease. The introduction of AMX0035 and tofersen marks a significant shift toward therapies that target intracellular stress pathways and genetic mutations, respectively. In parallel, agents such as masitinib and reldesemtiv demonstrate that addressing neuroinflammation and improving muscle function are equally critical strategies. Moreover, innovative approaches like NurOwn and the promising preclinical candidate NU-9 add further diversity to the therapeutic arsenal, hinting at the possibility of personalized treatments that cater to the heterogeneity of ALS. 

From a general perspective, the recent developments address the inherent shortcomings of past therapies while introducing novel mechanisms—whether through direct molecular inhibition, modulation of cellular stress responses, or even via cell-based supportive techniques. Specifically, individually tailored therapies like tofersen emphasize genetic stratification, whereas combined agents such as AMX0035 work on core pathogenic processes common to most ALS patients. Comparative effectiveness studies indicate that multimodal approaches might eventually provide superior clinical benefits, though challenges such as delivery, biomarker development, and trial design remain. 

Looking ahead, future prospects in ALS drug development include employing combination therapies, digital health for remote monitoring, and advanced drug delivery systems to break through current barriers. Additionally, a more refined understanding of ALS subtypes along with personalized, gene-targeted treatments will likely revolutionize the treatment paradigm. The emerging focus on harmonizing regulatory guidelines and leveraging multidisciplinary collaboration gives further promise that the next generation of ALS treatments may finally offer clinically meaningful outcomes and improved quality of life for patients. 

In conclusion, while significant challenges persist in treating ALS, the new drugs emerging on the clinical and preclinical frontlines provide strong evidence that a more effective, multifaceted treatment strategy is on the horizon. Continued investment in research, improved clinical trial design, and robust biomarker development are essential to ensure these innovative therapies transition successfully from the laboratory to routine clinical practice, ultimately fulfilling the long-standing promise of improved patient outcomes in ALS.

For an experience with the large-scale biopharmaceutical model Hiro-LS, please click here for a quick and free trial of its features！